Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance

Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance

Introduction and Objectives: In clinical trials, patients with hepatitis C virus (HCV) genotype (GT)1a infection and baseline resistance-associated substitutions (RASs) at amino acid positions 28, 30, 31, or 93 receiving elbasvir/grazoprevir for 12 weeks achieved lower rates of sustained virologic r...

Full description

Bibliographic Details
Main Authors: Deanna D. Hill, Jennifer R. Kramer, Kassie R. Chaffin, T. Christopher Mast, Michael N. Robertson, Fasiha Kanwal, Barbara A. Haber
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Annals of Hepatology
Subjects:
Hepatitis C virus
Baseline resistance
DAA
NS5A
treatment
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268123000030

Internet

http://www.sciencedirect.com/science/article/pii/S1665268123000030

Similar Items